Spots Global Cancer Trial Database for Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
Official Title: OXC4P1-105: A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Combretastatin A4 Phosphate Given in Combination With Bevacizumab to Subjects With Advanced Solid Tumors
Study ID: NCT00395434
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced solid tumors. The maximum tolerated dose will be defined if it is at one of the three dose levels under study.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Contact Details
Name: Paul Nathan, MD
Affiliation: Mount Vernon Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Hillori Connors, MS
Affiliation: Mateon Therapeutics
Role: STUDY_DIRECTOR
Name: Peter Harris, MD
Affiliation: Mateon Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
